Article

J&J hit with $1.2 Billion Penalty in Drug Case

An Arkansas judge slapped Johnson & Johnson and a subsidiary with more than $1.2 billion in penalties on Wednesday for deceptive marketing of the antipsychotic drug Risperdal.

The ruling marks the latest legal headache for J&J over the drug. Johnson & Johnson has faced lawsuits in a total of 11 states in connection with Risperdal.

Read the full story: http://hcp.lv/IJ94hi

Source: CNN Money

Related Videos
Ticiana Leal, MD
James Chambers, PhD
Mabel Mardones, MD.
1 KOL is featured in this series.
1 KOL is featured in this series.
Justin Oldham, MD, MS, an expert on IPF
Dr Bonnie Qin
Related Content
Global health | Image Credit: © zephyr_p - stock.adobe.com
November 14th 2024

Worldwide Incidence, Prevalence of MG Has More Than Doubled Since 1950s

AJMC Contributor
The data come from a systematic review of over 90 studies between 1952 through 2022, which found that both prevalence and incidence rates have than doubled throughout the study period.
Managed Care Cast
October 29th 2024

Breaking the Cycle: The Importance of Early Intervention in Hidradenitis Suppurativa

Giuliana Grossi
Prompt care supports mental well-being, as hidradenitis suppurativa is often associated with depression and anxiety due to its physical and social challenges.
Screenshot of an interview with Rebekah Walker, PhD
November 14th 2024

Diverse Offerings Inspiring Meaningful Change: A Preview of AHA 2024

Kyle Munz
Rebekah Walker, PhD, a first-time participant from the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, shares the offerings and opportunities at the 2024 American Heart Association (AHA) meeting that excited her and her team.
managed care cast logo
October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick
On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Researcher working with microplate in the laboratory | Image credit: angellodeco – stock.adobe.com
November 14th 2024

Sarepta Halts Development, Testing of DMD Therapy SRP-5051

Hayden E. Klein
Clinical development and trial testing of vesleteplirsen (SRP-5051) for Duchenne muscular dystrophy (DMD) was stopped, with the developer citing safety concerns, FDA feedback, and an evolving therapeutic landscape.
Woman holding a representation of a liver | Image credit: LIGHTFIELD STUDIOS - stock.adobe.com
November 14th 2024

Liver Cancer Risk Assessments: New Tool Beats Standard Screening

Laura Joszt, MA
A new risk score model for hepatocellular carcinoma using standard clinical data can better identify individuals at risk better than the current standard risk models.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo